跳至主要内容
临床试验/JPRN-jRCT1080223922
JPRN-jRCT1080223922已完成Unknown

Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets Survey on long-term use in type 2 diabetes mellitus patients with renal or hepatic impairment or advanced age

Takeda Pharmaceutical Company Limited0 个研究点目标入组 1,026 人开始时间: 2018年6月1日最近更新:
适应症

试验速览

阶段
Unknown
状态
已完成
入组人数
1,026

研究概览

简要总结

The results above showed no new concerns regarding the long-term safety and efficacy of this drug in patients with type 2 diabetes mellitus with renal or hepatic impairment or advanced ages (>= 65 years) and suggested a relationship between the improvement in the medication adherence after switching medication to this product and efficacy in participants taking alogliptin benzoate and metformin hydrochloride in combination.

研究设计

研究类型
Observational

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • Participants should meet one or more of the following:
  • 1. Have renal impairment (mild)
  • 2. Have hepatic impairment (mild or moderate)
  • 3. Elderly (aged 65 years or more)

排除标准

  • Participants with any contraindication for study drug.

研究者

相似试验